Overview

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study is a phase 2 study in patients with essential hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination